M. Alabdalaali, Mustafa, M. Hadi, Ali. (1401). A comparative study of antiretroviral (Lopinavir/ritonavir) and Remdesivir used in the pandemic in Iraq on the clinical outcome in patients with SARS-CoV-2. سامانه مدیریت نشریات علمی, (), -. doi: 10.22092/ari.2022.360354.2574
Mustafa M. Alabdalaali; Ali M. Hadi. "A comparative study of antiretroviral (Lopinavir/ritonavir) and Remdesivir used in the pandemic in Iraq on the clinical outcome in patients with SARS-CoV-2". سامانه مدیریت نشریات علمی, , , 1401, -. doi: 10.22092/ari.2022.360354.2574
M. Alabdalaali, Mustafa, M. Hadi, Ali. (1401). 'A comparative study of antiretroviral (Lopinavir/ritonavir) and Remdesivir used in the pandemic in Iraq on the clinical outcome in patients with SARS-CoV-2', سامانه مدیریت نشریات علمی, (), pp. -. doi: 10.22092/ari.2022.360354.2574
M. Alabdalaali, Mustafa, M. Hadi, Ali. A comparative study of antiretroviral (Lopinavir/ritonavir) and Remdesivir used in the pandemic in Iraq on the clinical outcome in patients with SARS-CoV-2. سامانه مدیریت نشریات علمی, 1401; (): -. doi: 10.22092/ari.2022.360354.2574
A comparative study of antiretroviral (Lopinavir/ritonavir) and Remdesivir used in the pandemic in Iraq on the clinical outcome in patients with SARS-CoV-2
Background: The SARS-CoV-2 virus, which emerged in December 2019, has infected millions of people worldwide and has been attributed to a large number of deaths. Due to the large number of mortalities, a number of studies assessed the effectiveness of some drugs in the fight against COVID-19, mainly by reducing the hospitalization rate among elderly and compromised patients. Among the drugs used to treat covid-19 was lopinavir-ritonavir combination, and Remdesivir. Due to considerable differences in effectiveness and clinical outcomes between the two treatments, this study compared the clinical outcomes of covid-19 patients treated with antiretrovirals (Lopinavir/ritonavir) and Remdesivir. Method: a total of 33 patients on Lopinavir/ritonavir and 35 patients on Remdesivir were selected for this study. Using a retrospective approach, a comparative analysis was conducted on the basis of demographics, hospital stay, laboratory parameters of C-reactive protein and plasma blood oxygen saturation, clinical treatment, as well as a clinical outcome assessment extracted from hospital Archive Data. Results: Both treatments improved patient outcomes, yet there was a significant difference between the Lopinavir/ritonavir and Remdesivir groups based on PLT, CRP, SPO2, and Mono results, with Remdesivir showing better clinical outcomes. No significant difference was reported in WBC, LYMPH, and LDH between the two treatments. It is still necessary to conduct further research to determine how effective both treatments are in treating severe covid-19 patients due to the limited number of available studies, and the inconsistent in the research methods and measurments used.